Palo Biofarma, S.L   Report issue

For profit Phase 1 Phase 2
Founded: Barcelona Spain (2006)

Organization Overview

First Clinical Trial
2012
NCT01691924
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

pbf-680 (3 trials)

Drugs in Phase 1 Trials (2)

pbf-509 (2 trials)

pbf-999 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 1)

Huntington Disease (Phase 1)

Parkinson Disease (Phase 1)

Respiratory Hypersensitivity (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 3